Secretory High-Mobility Group Box 1 Protein Affects Regulatory T Cell Differentiation in Neuroblastoma Microenvironment In Vitro

Figure 5

Association between HMGB1 expression in tumors and clinical outcomes in 498 neuroblastoma patients. Forest plot demonstrated that HMGB1 mRNA upregulation was an independent risk of poor clinical outcomes including disease progression, relapse, or death. MYCN amplification, a strong prognostic factor of neuroblastoma, was included in the model to adjust the contributed risk of HMGB1 mRNA alterations. Upregulation and downregulation of HMGB1 mRNA were defined as the z-score >1.25 and <-1.25, respectively. Data were made available in Supplementary Table 5.